Wockhardt Limited (NSE:WOCKPHARMA)
1,834.90
+18.20 (1.00%)
Jul 15, 2025, 3:30 PM IST
Wockhardt Revenue
In the fiscal year ending March 31, 2025, Wockhardt had annual revenue of 30.12B INR with 6.43% growth. Wockhardt had revenue of 7.43B in the quarter ending March 31, 2025, with 1.50% growth.
Revenue
30.12B
Revenue Growth
+6.43%
P/S Ratio
9.86
Revenue / Employee
12.62M
Employees
2,386
Market Cap
297.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 30.12B | 1.82B | 6.43% |
Mar 31, 2024 | 28.30B | 1.73B | 6.51% |
Mar 31, 2023 | 26.57B | -5.73B | -17.74% |
Mar 31, 2022 | 32.30B | 5.22B | 19.28% |
Mar 31, 2021 | 27.08B | -1.36B | -4.78% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 272.67B |
Mankind Pharma | 122.07B |
Apollo Hospitals Enterprise | 217.94B |
Zydus Lifesciences | 232.42B |
Aurobindo Pharma | 317.24B |
Glenmark Pharmaceuticals | 134.35B |
Wockhardt News
- 4 days ago - Wockhardt exits US generics business to focus on innovative portfolio - Business Upturn
- 2 months ago - Senores Pharmaceuticals acquires USFDA-approved ANDA for Enalapril Maleate Tablets from Wockhardt - Business Upturn
- 2 months ago - Senores Pharmaceuticals share price jumps 3% after company acquires ANDA for Topiramate tablets from Wockhardt - Business Upturn
- 2 months ago - Senores Pharmaceuticals acquires ANDA for Topiramate tablets from Wockhardt - Business Upturn
- 3 months ago - Wockhardt shares climb 3% as breakthrough antibiotic Zaynich™ saves US cancer patient with drug-resistant infection - Business Upturn
- 3 months ago - Wockhardt’s novel antibiotic Zaynich™ helps save US child cancer patient battling superbug infection - Business Upturn
- 5 months ago - Wockhardt reports Q3 Results: Revenue up 3% to Rs 721 crore, Net profit at Rs 20 crore vs loss of Rs 86 crore YoY - Business Upturn
- 5 months ago - Wockhardt shares surge 10% as flagship antibiotic Zaynich demonstrates breakthrough clinical success - Business Upturn